The Alzheimer’s Drug Discovery Foundation and the Association of Frontotemporal Degeneration, under the Treat Frontotemporal Degeneration fund, invite letters of intent for their clinical trials for frontotemporal degeneration (FTD) . This supports innovative clinical trials testing novel or re-purposed drugs for frontotemporal degeneration and related disorders. Trials should address both genetic and sporadic forms of FTD and related disorders, including behavioural variant FTD, primary progressive aphasia, corticobal syndrome, amyotrophic lateral sclerosis.
Funding & Duration
Grants are worth between USD $500,000 and $2M each (approx. AUD $706,000 and $2.8M), for a period of one to three years.
Private and public non-profit and for-profit institutions may apply. Partnerships and co-funding with industry are accepted. Leveraging of existing resources, clinical coordination centres or networks and patient registries are highly encouraged.
Submission Requirements & Due Dates
- 9 November 2018 – Letter of Intent (LOI)
- 8 February 2019 – full applications submitted (by invitation only) for internal review.
- Please email firstname.lastname@example.org if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review